Lyell Immunopharma, Inc. (LYEL): Price and Financial Metrics


Lyell Immunopharma, Inc. (LYEL): $4.11

-0.03 (-0.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LYEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LYEL POWR Grades

  • LYEL scores best on the Growth dimension, with a Growth rank ahead of 73.25% of US stocks.
  • The strongest trend for LYEL is in Value, which has been heading up over the past 179 days.
  • LYEL ranks lowest in Momentum; there it ranks in the 4th percentile.

LYEL Stock Summary

  • LYELL IMMUNOPHARMA INC's stock had its IPO on June 17, 2021, making it an older stock than merely 4.58% of US equities in our set.
  • LYEL's price/sales ratio is 26.39; that's higher than the P/S ratio of 95.2% of US stocks.
  • Revenue growth over the past 12 months for LYELL IMMUNOPHARMA INC comes in at 267.31%, a number that bests 96.66% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LYELL IMMUNOPHARMA INC are BLUE, SITM, SNAP, U, and IONQ.
  • Visit LYEL's SEC page to see the company's official filings. To visit the company's web site, go to www.lyell.com.

LYEL Valuation Summary

  • In comparison to the median Healthcare stock, LYEL's price/earnings ratio is 117.24% lower, now standing at -4.
  • LYEL's EV/EBIT ratio has moved up 15.3 over the prior 18 months.

Below are key valuation metrics over time for LYEL.

Stock Date P/S P/B P/E EV/EBIT
LYEL 2022-11-25 26.5 1.3 -4.0 -3.8
LYEL 2022-11-23 26.9 1.3 -4.1 -3.9
LYEL 2022-11-22 27.3 1.3 -4.1 -3.9
LYEL 2022-11-21 27.5 1.3 -4.2 -4.0
LYEL 2022-11-18 28.0 1.3 -4.2 -4.0
LYEL 2022-11-17 28.1 1.3 -4.3 -4.1

LYEL Price Target

For more insight on analysts targets of LYEL, see our LYEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.50 Average Broker Recommendation 1.38 (Strong Buy)

LYEL Stock Price Chart Interactive Chart >

Price chart for LYEL

LYEL Price/Volume Stats

Current price $4.11 52-week high $10.33
Prev. close $4.14 52-week low $3.57
Day low $4.07 Volume 888,200
Day high $4.34 Avg. volume 1,040,996
50-day MA $6.01 Dividend yield N/A
200-day MA $5.94 Market Cap 1.02B

Lyell Immunopharma, Inc. (LYEL) Company Bio


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


LYEL Latest News Stream


Event/Time News Detail
Loading, please wait...

LYEL Latest Social Stream


Loading social stream, please wait...

View Full LYEL Social Stream

Latest LYEL News From Around the Web

Below are the latest news stories about LYELL IMMUNOPHARMA INC that investors may wish to consider to help them evaluate LYEL as an investment opportunity.

Is Lyell Immunopharma Inc. (NASDAQ: LYEL) Still A Buy After A -11.09% Weekly Drop?

During the last session, Lyell Immunopharma Inc. (NASDAQ:LYEL)’s traded shares were 1.11 million. At the end of the trading day, the stock’s price was $4.41, reflecting an intraday loss of -0.90% or -$0.04. The 52-week high for the LYEL share is $11.41, that puts it down -158.73 from that peak though still a striking 19.05% … Is Lyell Immunopharma Inc. (NASDAQ: LYEL) Still A Buy After A -11.09% Weekly Drop? Read More »

Marketing Sentinel | November 18, 2022

Can you now get a good deal on Lyell Immunopharma Inc.’s shares?

Lyell Immunopharma Inc. (NASDAQ:LYEL) marked $4.70 per share on Monday, up from a previous closing price of $4.53. While Lyell Immunopharma Inc. has overperformed by 3.75%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LYEL fell by -58.74%, with highs and lows ranging from $11.63 to […]

US Post News | November 15, 2022

Earnings Beat: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Shareholders in Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) had a terrible week, as shares crashed 20% to US$4.53 in the...

Yahoo | November 12, 2022

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will participate in the Barclays Virtual Fireside Chat Series on Thursday, November 17, at 11 a.m., ET. A webcast of the presentation can be accessed through the investor relations section of the Company’s websi

Yahoo | November 10, 2022

Lyell Immunopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Lyell Immunopharma ( NASDAQ:LYEL ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.0k (down 100% from 3Q...

Yahoo | November 10, 2022

Read More 'LYEL' Stories Here

LYEL Price Returns

1-mo -30.10%
3-mo -42.60%
6-mo -18.45%
1-year -56.96%
3-year N/A
5-year N/A
YTD -46.90%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.733 seconds.